Lp(a),first identified by Berg in 1963 as a genetic variant of low-density lipoproteins (LDL) [6] , consists of a lipidcore associatedwith apoprotein (apo) B-l00, a highmolecular-mass hydrophobic proteindisulfide-linked to apo(a), LDL-Chol, low-density lipoprotein cholesterol; and BMI, body mass index.
Received October 6, 1995; accepted March 1, 1996. a highly glycosylated and hydrophilic protein. Apo(a) is structurally similar to plasminogen, consisting also of kringle-like and protease-like domains [1] [2] [3] [4] . Several different polymorphs of apo(a) that differ in the number of kringle type 2 units in the kringle domain, and hence in molecular mass, have been identified by electrophoresis.
Apo(a) polymorphs are inherited as an autosomal codominant genetic trait, and their molecular mass is strictly and inversely related to Lp(a) blood concentration [1] [2] [3] [4] ; genetic factors are thus thought to be the major determinants of Lp(a) circulating concentrations. However, endogenous hormones, especially sex steroids, can contribute to the inter-and intraindividual variability of Lp(a) concentrations.
Sex-related differences in Lp(a) concentrations have not yet been found /7, 8] ; an increase recently observed in women after menopause [9] was not confirmed [10] . Estrogen replacement therapy in association with progestogen can induce a decrease of Lp(a) [11, 12] , whereas unopposed estrogen treatment in relatively low doses has no significant effects on Lp(a), at least in the short term [13] .
In humans, both androgens [13] [14] [15] [17, 18] or premenopausal women [19] , with the exception of a positive correlation to dehydroepiandrosterone sulfate, found in men [18] .
Only one study has addressed the effectsof changes in concentrations of endogenous sex steroids on Lp(a); it concerned the response of Lp(a) to orchidectomy in elderly men affected by prostate cancer [16] . No data are available concerning the effects of chemical castration induced by gonadotropinreleasing hormone (GnRH) agonists, which can be used in Table 1 . Age, BMI, and lipid concentrations (mean ± SD) in patients and controls.
Age, years BMI, kg/rn2 All receivedmonthly subcutaneous 3.6-jLgdoses of GnRH agonist (goserelin) therapy, beginning at least6 months before the study.The averagelength of therapywas 11.6± 5.0 months. The patients had not been treated before.
We included in the study 16 patients(mean age ± SD 73 ± 6.6 years; age range 6 1-83) at clinical stage C2 (3 patients) or D (13 patients), who had not been previouslytreatedfor prostate cancer.As with the cross-sectional study,allstage D patients showed metastatic involvement of the bones only. We examined allpatientsat baseline and after3 months of subcutaneous goserelin therapy alone (3.6 jtg/month) or goserelin (same dosage) plus flutamide,250 mg orallythree times a day, and asked them to not change their diets and or life-styles during the study.
We excluded patients and controls with diabetes mellitus, thyroid disease, severe renal or liver failure, or acute or chronic inflammatory disease and consumers of excessive alcohol from the study. No patients were taking medications known to influence lipoprotein metabolism, and all patients and controls gave their informed consent. The study was approved by the Ethical Committee of the University of Parma. Blood samples for lipid assay were drawn at 0800-0900, after the patients had fasted for 12 h. Samples from the 16 patients not previously treated were also assayed for testosterone ('I') and estradiol (E2) at each examination.
Samples were centrifuged at 1000g for 10 mm, and the serum was stored at -80 #{176}C until assay. although the differences in HDL-Chol and apo A-I were not statistically significant, the higher ratio between apo A-I and HDL-Chol suggested some changes in HDL particle composition. Table 3 shows hormone and lipidconcentrationsbefore and afterchemical castration in allpatientsand in subsetsaccording to treatment (goserelin or goserelin plus flutamide).
BaselineLp(a) concentrationsin untreatedpatientswere not significantly lower than in the crosssectional study controls. A significant difference was apparent for apo A-I concentrations,which were lower in untreated patients than in age-matched controls, although apo A-IJHDLChol ratios were similar. However, untreated patients and healthy controls were matched for age and BMII.
Both treatments induced a drastic reduction of T and E2
concentrations. Ifwe consider allpatientsas one group, independent of treatment,the mean serum T and E2 concentrations decreased by 91% and 62%, respectively. We found no significant difference between hormone decreases in the two treatment subsets, although the percent change in E2 was slightly lower in patients treated by combined therapy (67% vs 77%).
The E2 decline in response to combined therapy was not significant (P = 0.05); indeed, when we considered individual responses, one patient with the lowest baseline concentrations had a slight treatment-inducedincreaseratherthan a decreaseof E2 concentrations. No consistent change was apparentforLp(a), whereas apo A-I increased in both subsets (significantly, only in patients treated by combination therapy). HDL-Chol also increased, so that the apo A-I/HDL-Chol ratio did not change. Only 13-coefficients of significant correlations are presented.
Also, HDL-Chol, much like apo A-I, changed significantly only in patientsreceivingcombined treatment.
A wide interindividual variability in individualserum Lp(a) concentrationsnecessitatedagglomerative hierarchical cluster analysis (Table 4) . We identified three classes of patients and two individual casesthatdid not combine: cluster I,10 patients (Table 4) .
Wilcoxon tests performed separately on cluster I subjects confirmed significant (P = 0.02) increases in Lp(a) concentrations in response to treatment.
Finally, stepwiseregressionanalysis was performed for each lipid,consideringallrelative changes as dependent variables, and hormone and other lipoproteinvariationsas well as lipid baseline concentrations as independent covariates. Table  5 shows a summary of this analysis, indicating only the significantly related covariates.
Lp(a) relative changes were significandy inversely related to T changes; we found no correlation between Lp(a) changes and other lipoprotein concentrations.
HDL-Chol, apo A-I, and Tg relative increaseswere inversely relatedto baselineconcentrationsonly, and we observed no significant correlation between lipid and sex steroid changes except an inverseassociation between LDL-Chol and E2.
Discussion
Surgicaland pharmacologicalcastration of patientsaffectedby prostate cancer has been widely used as an experimental model to study the effects of changes in endogenous sex steroid concentrations on lipid metabolism. In this study, we found no consistent changes in Lp(a) blood concentrations in response to treatment with a GnRH agonist, administered alone or in combination with an antiandrogen. The cross-sectional comparison of patientstreated with combination therapy and age-matched healthycontrolsshowed no significant differences in Lp(a) concentrations. However, possible interference of confounding variables such as nutritional status, diet, and physicalactivity must be consideredwhen interpreting these data. We expressed nutritional status as BMI, which in the elderly [22] is not a reliable index of body composition of fat and fat-free mass percentages. However, we previously reported the lack of any significant correlation between Lp(a) and body composition assessedby anthropometry in healthy males [18] . On the contrary, at least in diabetic adolescents, physical fitness affects Lp(a) [23] . Some reports on Table 5 . Stepwise multiple regression analysis relating ilpoprotein relative changes, hormone relative changes, and baseline values.
Change % HDL-Choi.
Change % LDL-Choi. the decreasing effect of o-3 polyunsaturated free fatty acids also suggest that diet could affect Lp(a) metabolism [24, 25] . However, our study concentrates on elderly patients; consequently, theirdietsand levels of physicalactivity probably did not differ significantly among them. Other sources of bias could interfere in the interpretation of cross-sectional data,such as the great inter-and intraindividual variability of Lp(a) concentrations. Finally, cancer per se could influence Lp(a) as an acute-phase protein,independent of any hormonal treatment [26, 27] .
The aim of the second part of our study (the 16 untreated patients)
was to limit these sources of bias, especially Lp(a) interindividual variability. Here, patients were enrolled shortly aftercancer diagnosis, at an earlier stageof diseasethan in the cross-sectional study, and were reexamined after only 3 months of therapy to limittumor-caused changes in lipid metabolism.
As in the cross-sectional study, no changes in Lp(a) concentrations were found after 3 months of treatment, despite significant changes in sex steroid concentrations and other lipids, mainly HDL-Chol and apo A-I. However, regression analysis correlating relative changes of Lp(a) to those of sex steroids showed an independent and inverse relation between Lp(a) and
T. In addition,clusteranalysisdefined a subgroup of patients (cluster I) representing 62.5% of cases, showing a slight but significant increase of Lp(a) in response to androgen suppression. Cluster I patients also showed greater decreases of T and E2 concentrationsthan did the other patients. This suggeststhat both steroidscan affectLp(a) metabolism in the same way, which means that an increase in Lp(a) can be detected only if both steroidconcentrationsdecrease enough. Indeed, the two cluster II patients differed from cluster I patients because they both had lower increasesof Lp(a) and lower decreasesof E2 concentrations.
In this context, the higher increase of Lp(a) reported after orchidectomy [16] could be accounted forby the greaterdecline of E2 concentrations after surgical castration. In our study, androgen suppressionwas achieved by a GnRH agonist, which reduces lutropin (LH) secretion by down-regulating GnRH receptors in the pituitary gland, causing reduction of testosterone to castrationconcentrations. Because greaterE2 declines were reported after orchidectomy (85%) than after GnRH agonist therapy (54%) [28] , we suggestthatdifferent castration methods can cause variations of E2 decreases and consequently can leadto variations in Lp(a) results. Contrarily, we thinkthat complete androgen blockade, as induced by flutamide, has no other effects on Lp(a), since we found no significant difference between the two different treatments (GnRH agonist and GnRH agonist plus flutamide).
Thus, in agreement with previous reports, we suggest that both endogenous E2 and androgen could reduce Lp(a) concentrations. However, their influence seems to be slight and not easily detectable, and no significant correlation has been found among T, E,, and Lp(a) blood concentrations under physiological conditions, either in males [17, 18] or females [19] . Cluster analysis suggests that Lp(a)-increased response to androgen suppressioncould alsobe relatedto baselineconcentrations, since increases were greater among patients with lower Lp(a) concentrations.
Therefore, when we consider that Lp(a) blood concentrationsare inverselyrelatedto apo(a)molecular mass, we can suppose that different Lp(a) phenotypes respond differently to the same type of hormonal changes. However, Lp(a) responses to estrogen administrationor orchidectomy reportedly did not differ in relation to apo(a) phenotypes [16] .
Regarding the effects of androgen suppressionon the other lipids, our study confirms previous reports [28, 29] that show increases of HDL-Chol and apo A-I caused by the reduced activity of hepatic lipase-the enzyme responsiblefor HDL2
catabolism-as well as the increased production of apo A-I. Also in our study, the smaller E2 decrease induced by chemical castration in comparison with orchidectomy could playa rolein HDL response to GnRH agonist, since surgical castration does not induce changes in HDL components, notwithstanding similar T declines [16, 28] . Furthermore, HDL-Chol and apo
A-I increaseswere significant only in patientsreceivingcombined treatment, suggesting that a complete androgen blockade, and consequently an absence of adrenal androgen action,can lead to greater effects on HDL metabolism.
However, cross-sectional study resultssuggest that among HDL particle components, apo A-I ismost affectedby androgen, and apo A-I concentrationsremain higher afterprolonged treatment, notwithstanding HDL-Chol concentrations similar to those of controls. This means that the apo A-IIHDL-Chol ratio is higher in castrated patients affected by prostate cancer.
We did not considerthe complex relations between cancer and lipoproteinmetabolism in this study. However, a decrease of HDL-Chol has been found in patients affected by cancer such as acute and chronic leukemia [30, 31] , non-Hodgkin lymphoma [30] , and breast cancer [32] . In this context, the lower Tg concentrations in castrated patients could be interpreted as a consequence of diseaseand not of treatment,sinceour prospective study, as well as other previous reports [28, 29] , did not show any changes in Tg concentrations after androgen suppression. 
